Jeffrey M Venstrom
Overview
Explore the profile of Jeffrey M Venstrom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahal B, Margolis M, Hubbell E, Chen C, Venstrom J, Abran J, et al.
JCO Precis Oncol
. 2024 Aug;
8:e2400269.
PMID: 39208374
Purpose: Indolent prostate cancer (PCa) is prevalent in the intended use population (adults age 50-79 years) for blood-based multicancer early detection (MCED) tests. We examined the detectability of PCa by...
2.
Laurent C, Flores M, Chartier L, Huet S, Bolen C, Venstrom J, et al.
Br J Haematol
. 2023 May;
202(3):686-689.
PMID: 37218065
No abstract available.
3.
Sivakumar S, Jin D, Tukachinsky H, Murugesan K, McGregor K, Danziger N, et al.
Nat Commun
. 2022 Dec;
13(1):7495.
PMID: 36470901
Pathological and genomic profiling have transformed breast cancer care by matching patients to targeted treatments. However, tumors evolve and evade therapeutic interventions often through the acquisition of genomic mutations. Here...
4.
Alshalalfa M, Nguyen T, Stopsack K, Khan A, Franco I, Seldon C, et al.
Urol Oncol
. 2022 Nov;
41(2):106.e17-106.e23.
PMID: 36400666
Objective: Chromosome 8q arm (chr8q) is the most amplified chromosomal segment in advanced metastatic castration-resistant prostate cancer after chXq12. These regions harbor important oncogenes driving prostate cancer progression, including MYC...
5.
Sammons S, Raskina K, Danziger N, Alder L, Schrock A, Venstrom J, et al.
JCO Precis Oncol
. 2022 Oct;
6:e2200149.
PMID: 36315915
Purpose: APOBEC mutagenesis underlies somatic evolution and accounts for tumor heterogeneity in several cancers, including breast cancer (BC). In this study, we evaluated the characteristics of a real-world cohort for...
6.
Gounder M, Agaram N, Trabucco S, Robinson V, Ferraro R, Millis S, et al.
Nat Commun
. 2022 Jun;
13(1):3406.
PMID: 35705558
There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome this challenge by providing insight...
7.
Myer P, Lee J, Madison R, Pradhan K, Newberg J, Isasi C, et al.
Cancer Discov
. 2022 Feb;
12(5):1282-1293.
PMID: 35176763
Significance: KRAS (particularly KRASG12D/G13), APC, and PIK3CA were more frequently altered in AFR who had a lower frequency of MSI-H tumors. There were no differences in actionable kinase driver alterations....
8.
Zhang L, Hamdani O, Gjoerup O, Cho-Phan C, Snider J, Castellanos E, et al.
JCO Precis Oncol
. 2022 Jan;
6:e2100330.
PMID: 35050711
Purpose: Human epidermal growth factor receptor 2 (HER2) overexpression or amplification (amp) are biomarkers for approved anti-HER2 therapies. amp may better predict response compared with immunohistochemistry or in situ hybridization,...
9.
Graf R, Fisher V, Mateo J, Gjoerup O, Madison R, Raskina K, et al.
Eur Urol
. 2021 Oct;
81(1):37-47.
PMID: 34716049
Background: Biomarkers predicting second-generation novel hormonal therapy (NHT) benefit relative to taxanes are critical for optimized treatment decisions for metastatic castration-resistant prostate cancer (mCRPC) patients. These associations have not been...
10.
Lee J, Madison R, Classon A, Gjoerup O, Rosenzweig M, Frampton G, et al.
JCO Precis Oncol
. 2021 Sep;
5.
PMID: 34476332
Purpose: exon 14 (ex14) skipping alterations are oncogenic drivers in non-small-cell lung cancer (NSCLC). We present a comprehensive overview of ex14 samples from 1,592 patients with NSCLC, associated clinicogenomic characteristics,...